Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PSMAddition phase 3 trial of 177Lu-PSMA-617 plus standard therapy versus standard therapy alone in metastatic hormone-sensitive prostate cancer
CTR20221475Phase 3Active
- Sponsor
- Novartis
- Start
- Oct 2022
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptide-Drug Conjugates → Peptide Conjugates → Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of lutetium lu 177 vipivotide tetraxetan in prostate cancer (PCa), sponsored by Novartis. Started Oct 2022; status: active.
02
Drugs
lutetium lu 177 vipivotide tetraxetan
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on CTR20221475.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221475.